Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
SELLAS Life Sciences Group Inc (NASDAQ: SLS) closed the day trading at $2.77 up 4.92% from the previous closing price of $2.64. In other words, the price has increased by $4.92 from its previous closing price. On the day, 9.27 million shares were traded. SLS stock price reached its highest trading level at $2.975 during the session, while it also had its lowest trading level at $2.64.
Ratios:
For a better understanding of SLS, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.28 and its Current Ratio is at 8.28. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In the most recent recommendation for this company, Cantor Fitzgerald on July 21, 2021, initiated with a Overweight rating and assigned the stock a target price of $18. On April 02, 2018, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $11.H.C. Wainwright initiated its Buy rating on April 02, 2018, with a $11 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 19 ’25 when Kalin Katherine Bach bought 63,400 shares for $1.59 per share. The transaction valued at 100,806 led to the insider holds 104,400 shares of the business.
VAN NOSTRAND ROBERT L bought 10,000 shares of SLS for $14,800 on Jun 12 ’25. The Director now owns 20,400 shares after completing the transaction at $1.48 per share. On May 30 ’25, another insider, Wasman Jane, who serves as the Director of the company, bought 20,000 shares for $1.69 each. As a result, the insider paid 33,800 and bolstered with 30,400 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SLS now has a Market Capitalization of 408415008 and an Enterprise Value of 350844000.
Stock Price History:
The Beta on a monthly basis for SLS is 2.37, which has changed by 1.6138613 over the last 52 weeks, in comparison to a change of 0.13927746 over the same period for the S&P500. Over the past 52 weeks, SLS has reached a high of $2.66, while it has fallen to a 52-week low of $0.85. The 50-Day Moving Average of the stock is 51.45%, while the 200-Day Moving Average is calculated to be 65.44%.
Shares Statistics:
Over the past 3-months, SLS traded about 4.59M shares per day on average, while over the past 10 days, SLS traded about 6553930 shares per day. A total of 142.44M shares are outstanding, with a floating share count of 141.07M. Insiders hold about 0.97% of the company’s shares, while institutions hold 23.22% stake in the company. Shares short for SLS as of 1764288000 were 33260681 with a Short Ratio of 7.25, compared to 1761868800 on 28964581. Therefore, it implies a Short% of Shares Outstanding of 33260681 and a Short% of Float of 23.52.
Earnings Estimates
The stock of SELLAS Life Sciences Group Inc (SLS) is currently drawing attention from 3.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is -$0.07, with high estimates of -$0.05 and low estimates of -$0.09.
Analysts are recommending an EPS of between -$0.24 and -$0.29 for the fiscal current year, implying an average EPS of -$0.27. EPS for the following year is -$0.32, with 3.0 analysts recommending between -$0.2 and -$0.38.
